Preparation and in vitro evaluation of oxybutynin transdermal gel formulations

Abdullah Mrad, Hind El-Zein an

Abstract

Oxybutynin (OXB) is one of the most used medications to treat urinary incontinence especially in older population. Because of the first pass metabolism which produce the active metabolite N-Desethyl-Oxybutynin the reason for adverse side effects especially dry mouth, topical gel formulations were developed using Carbopol ETD2020 (0.5%, 1%), Poloxamer 407 (2%) , Hydroxy Ethyl Cellulose HEC (1%, 2%), Hydroxy Propyl Methyl Cellulose HPMC (2%, 4%). These formulations were evaluated for drug content, pH determination, viscosity measurement at 25oC and 37oC, and for in-vitro drug release using Enhancer Cell, In order to reach the best formulation, which is effective, and can reduces the adverse side effects. Then a comparison was made with the brand product. Among all the prepared formulations, F1 and F2 formulations prepared by using 0.5% and 1% Carbopol ETD2020 respectively, were the best because they exhibited the best in-vitro drug release, and there were no statistical differences in the drug release from F1 and F2 formulations and the drug release from the brand product